Advertisement

Effect of some peptides on dopaminergic function in man

  • S. Lal
  • N. P. V. Nair
  • I. Isaac
  • J. Thavundayil
  • H. Guyda
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 29)

Summary

Thyrotropin-releasing hormone (TRH) (200 μg iv) and 1-desamino-8-D-arginine vasopressin (DDAVP) (4 μg iv) antagonized the growth hormone (GH) response to apomorphine HC1 (Apo) (0.5 mg sc) in 10 normal men. Apo had no effect on basal prolactin (PRL) levels but antagonized the PRL response to TRH. DDAVP plus Apo decreased PRL compared to placebo or DDAVP alone. These observations are compatible with (a) an inhibitory effect of TRH on hypothalamic and pituitary lactotrophe dopamine (DA) function (b) a fa-cilitory effect of DDAVP on lactotrophe DA function and an inhibitory effect on hypothalamic DA function. Whether these are direct or indirect effects on DA mechanisms is unclear.

Keywords

Growth Hormone Growth Hormone Secretion Growth Hormone Response BioI Psychiatry Basal Prolactin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Besses GS, Burrow GN, Spaulding SW, Donabedian RK (1975) Dopamine infusion acutely inhibits the TSH and the prolactin response to TRH. J Clin Endocrinol Metab 41: 985–987.PubMedCrossRefGoogle Scholar
  2. Blask DE, Vaughan MK, Champney TH, Johnson LY, Vaughan GM, Becker RA, Reiter RJ (1984) Opioid and dopamine involvement on prolactin release induced by arginine vasotocin and vasopressin in the male rat. Neuroendocrinology 38: 56–61.PubMedCrossRefGoogle Scholar
  3. Brambilla F, Agaglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R, Catalano M, Drago F (1986) Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 15: 114–121.PubMedCrossRefGoogle Scholar
  4. Brown PM, Baccus R, Sachs L, Sonksen PH, Wheeler M (1979) Bromocriptine suppression of TRH-stimulated prolactin and thyrotropin release and accompanying inhibition of bromocriptine-induced GH release by TRH in normal man. Clin Endocrinol 10: 481–488.CrossRefGoogle Scholar
  5. Burrow GN, May PB, Spaulding SW, Donabedian RK (1977) TRH and dopamine interactions affecting pituitary secretion. J Clin Endocrinol Metab 45: 65–71.PubMedCrossRefGoogle Scholar
  6. Chihara K, Kato Y, Maeda K, Abe H, Furumoto M, Imura H (1977) Effects of thyrotropin-releasing hormone on sleep and sleep-related growth hormone release in normal subjects. J Clin Endocrinol Metab 44: 1094–1100.PubMedCrossRefGoogle Scholar
  7. Chihara K, Kashio Y, Kita T, Okimura Y, Kaji H, Abe H, Fujita T (1986) L-Dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans. J Clin Endocrinol Metab 62: 466–473.PubMedCrossRefGoogle Scholar
  8. Delitala G, Maioli M, Pacifico A, Brianda S, Palermo M, Manelli M (1983) Cholinergic receptor control mechanism for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man. J Clin Endocrinol Metab 57: 1145–1149.PubMedCrossRefGoogle Scholar
  9. Funatsu K, Inanaga K (1987) Modulation of dopamine receptors by thyrotropin releasing hormone in the rat brain. Peptides 8: 319–325.PubMedCrossRefGoogle Scholar
  10. Guyda H (1975) Heterogeneity of human growth hormone and prolactin secreted in vitro: immunoassay and radioreceptor assay correlations. J Clin Endocrinol Metab 41: 953–967.PubMedCrossRefGoogle Scholar
  11. Heal DJ, Green AR (1979) Administration of thyrotropin releasing hormone (TRH) to rats releases dopamine in n. accumbens but not in n. caudatus. Neuropharmacology 18: 23–31.PubMedCrossRefGoogle Scholar
  12. Ho KY, Smythe GA, Lazarus L (1985) The interaction of TRH and dopamine mechanisms in the regulation of stimulated prolactin release in men. Clin Endocrinol 23: 7–16.CrossRefGoogle Scholar
  13. Hwang P, Guyda H, Friesen H (1971) A radioimmunoassay for human prolactin. Proc Natl Acad Sci 68: 1902–1906.PubMedCrossRefGoogle Scholar
  14. Ishikawa K, Katakami H, Frohman LA (1987) Neuroanatomical localization of the inhibitory effect of TRH on growth hormone secretion. Am J Physiol 253: E354–E359.PubMedGoogle Scholar
  15. Jolkkonen J, Lehtinen M, Soininen H, Sennef C, Riekkinen P (1987) Enhanced monoam-inergic neurotransmission by des-glycinamide-arginine vasopressin in human subjects. Neurosci Lett 76: 312–315.PubMedCrossRefGoogle Scholar
  16. Kerwin RW, Pycock CJ (1979) Thyrotropin releasing hormone stimulates the release of 3H-dopamine from slices of rat nucleus accumbens in vitro. Br J Pharmacol 67: 323–325.PubMedGoogle Scholar
  17. Kovacs GL, Vecsei L, Szabo G, Telegdy G (1977) The involvement of catecholamine mechanisms in the behavioral action of vasopressin. Neurosci Lett 5: 337–344.PubMedCrossRefGoogle Scholar
  18. Lal S (1988) Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropharmacol Biol Psychiatry 12: 117–164.CrossRefGoogle Scholar
  19. Lal S, Nair NPV (1984) Neuroendocrine evaluation of catecholaminergic function in man. In: Shah NS, Donald AG (eds) Psychoneuroendocrine dysfunction in psychiatric and neurological illnesses: influences of psychopharmacological agents. Plenum, New York, ch 27, pp 485–501.Google Scholar
  20. Lal S, de la Vega CE, Sourkes TL, Friesen HG (1972) Effect of apomorphine on human growth hormone secretion. Lancet ii: 661.CrossRefGoogle Scholar
  21. Lal S, de la Vega CE, Sourkes TL, Friesen HG (1973) Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab 37: 719–724.PubMedCrossRefGoogle Scholar
  22. Lal S, Martin JB, de la Vega CE, Friesen HG (1975) Comparison of the effect of apomorphine and L-dopa on serum growth hormone levels in normal men. Clin Endocrinol 4: 277–285.CrossRefGoogle Scholar
  23. Lal S, Guyda H, Bikadoroff S (1977) Effect of methysergide and pimozide on apomorphine-induced growth hormone secretion in men. J Clin Endocrinol Metab 44: 766–770.PubMedCrossRefGoogle Scholar
  24. Lal S, Nair NPV, Iskandar HI, Etienne P, Wood PL, Schwartz G, Guyda H (1982) Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. J Neural Transm 54: 75–84.PubMedCrossRefGoogle Scholar
  25. Lal S, Nair NPV, Eugenio H, Thavundayil J, Lizondo E, Wood PL, Etienne P, Guyda H (1983) Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 7: 537–544.PubMedCrossRefGoogle Scholar
  26. Lal S, Nair NPV, Thavundayil JX, Eugenio H, Guyda H (1984) Effect of isomers of sulpiride on prolactin and apomorphine-induced growth hormone secretion in normal subjects. XVth International Congress of the International Society for Psychoneu-roendocrinology, Vienna, July 15-19, abstract, p 106.Google Scholar
  27. Lewis BM, Dieguez C, Lewis M, Hall R, Scanlon MF (1986) Hypothalamic D2 receptors mediate the preferential release of somatostatin-28 in response to dopaminergic stimulation. Endocrinology 119: 1712–1717.PubMedCrossRefGoogle Scholar
  28. Maeda K, Kato Y, Chihara K, Ohgo S, Iwasaki H, Imura H (1975) Suppression by thyrotropin releasing hormone (TRH) of human growth hormone release induced by L-dopa. J Clin Endocrinol Metab 41: 408–11.PubMedCrossRefGoogle Scholar
  29. Marchesi C, Gnudi A, Chiodera P, De Risio C, Fava A, Dasso L, De Ferri A, Guerra M, Coiro V (1987) Involvement of a dopaminergic mechanism in the response of growth hormone to thyrotropin releasing hormone in patients with major depression. Phar-macopsychiatry 20: 64–66.Google Scholar
  30. Marcovitz S, Goodyer CG, Guyda H, Gardiner RJ, Hardy J (1982) Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture. J Clin Endocrinol Metab 54: 6–16.PubMedCrossRefGoogle Scholar
  31. Martin JB, Lal S, Tolis G, Friesen H (1974) Inhibition by apomorphine of prolactin secretion in patients with elevated serum prolactin. J Clin Endocrinol Metab 39: 180–182.PubMedCrossRefGoogle Scholar
  32. Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2: 19–76.PubMedGoogle Scholar
  33. Miyamoto M, Narumi S, Nagai Y, Shima T, Nagawa Y (1979) Thyrotropin-releasing hormone: hyperactivity and mesolimbic dopamine system in rats. Jpn J Pharmacol 29: 335–347.PubMedCrossRefGoogle Scholar
  34. Nair NPV, Lal S, Cervantes P, Yassa R, Guyda H (1979) Effect of clozapine on apo-morphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuropsychobiology 5: 136–142.PubMedCrossRefGoogle Scholar
  35. Nair NPV, Lal S, Iskandar HI, Etienne P, Wood PL, Guyda H (1982) Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull 8: 587–591.PubMedCrossRefGoogle Scholar
  36. Nair NPV, Lal S, Thavundayil JX, Wood PL, Etienne P, Guyda H (1984) CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man. Neuropeptides 4: 281–291.PubMedCrossRefGoogle Scholar
  37. Narumi S, Nagawa Y (1983) Modification of dopaminergic transmission by thyrotropin-releasing hormone. In: Segawa T (ed) Molecular pharmacology of neurotransmitter receptors. Raven Press, New York, pp 185–197.Google Scholar
  38. Nilsson KO, Wide L, Hokfelt B (1975) The effect of apomorphine on basal and TRH stimulated release of thyrotropin and prolactin in man. Acta Endocrinol 80: 220–229.PubMedGoogle Scholar
  39. Prasad C (1988) Neuropeptide-dopamine interactions. II. Cyclo (His-Pro) augmentation of amphetamine-but not apomorphine induced Stereotypie behaviour. Behav Brain Res 27: 241–245.PubMedCrossRefGoogle Scholar
  40. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313.PubMedGoogle Scholar
  41. Schimchowitsch S, Palacios JM, Stoeckel ME, Porte A (1986) Dopamine D2-receptors are restricted to the prolactin cells in rabbit pituitary gland: a combined autoradiographic and immunocytochemical study. Neurosci Lett 70: 314–319.PubMedCrossRefGoogle Scholar
  42. Shin SH (1982) Vasopressin has a direct effect on prolactin release in male rats. Neuroen-docrinology 34: 55–58.Google Scholar
  43. Shioda S, Kohara H, Nakai Y (1987) TRH axon terminals on synapsis with GRF neurons in the arcuate nucleus of the rat hypothalamus as revealed by double labeling im-munocytochemistry. Brain Res 402: 355–358.PubMedCrossRefGoogle Scholar
  44. Sorensen PS, Vilhardt H, Gjerris F, Warberg J (1984) Impermeability of the blood-cere-brospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. Eur J Clin Invest 14: 435–439.PubMedCrossRefGoogle Scholar
  45. Sourkes TL, Lal S (1975) Apomorphine and its relation to dopamine in the nervous system. Adv Neurochem 1: 247–299.Google Scholar
  46. Tanaka M, Versteeg DHG, de Wied D (1977) Regional effects of vasopressin on brain catecholamine metabolism. Neurosci Lett 4: 321–325.PubMedCrossRefGoogle Scholar
  47. Tapanainen P, Knip M, Lautala P, Leppaluoto J (1988) Variable plasma growth hormone (GH)-releasing hormone and GH responses to clonidine, L-dopa and insulin in normal men. J Clin Endocrinol Metab 67: 845–849.PubMedCrossRefGoogle Scholar
  48. Tsang D, Lal S (1977) Effect of monoamine receptor agonists and antagonists on cyclic AMP accumulation in human cerebral cortex slices. Can J Physiol Pharmacol 55: 1263–1269.PubMedCrossRefGoogle Scholar
  49. Van Heuven-Nolsen D, Versteeg DHG (1985) Interaction of vasopressin with the nigro-striatal dopamine system: site and mechanism of action. Brain Res 337: 269–276.PubMedCrossRefGoogle Scholar
  50. Xiao XS, Veldhius HD, Van Ree JM (1984) Neuropeptides related to neurohypophyseal hormones with apomorphine induced-behavioral changes. Neuropeptides 4: 237–245.PubMedCrossRefGoogle Scholar
  51. Yarbrough GG (1983) Thyrotropin releasing hormone and CNS cholinergic neurons. Life Sci 33: 111–118.PubMedCrossRefGoogle Scholar
  52. Zanoboni A, Zanoboni-Muciaccia W, Zanussi C, Baraldi R (1979) Suppression of clonidine-induced release of GH by thyrotropin releasing hormone in humans. J Endocrinol Invest 2: 347–351.PubMedGoogle Scholar
  53. Zlokovic BV, Segal MB, Begley DJ, Davson H, Rakic L (1978) Permeability of the blood cerebrospinal fluid and blood brain barriers for thyrotropin releasing hormone. Brain Res 358: 191–199.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • S. Lal
    • 1
    • 2
    • 4
  • N. P. V. Nair
    • 1
  • I. Isaac
    • 1
  • J. Thavundayil
    • 1
  • H. Guyda
    • 3
  1. 1.Douglas Hospital Research CentreVerdunCanada
  2. 2.Department of PsychiatryMontreal General HospitalVerdunCanada
  3. 3.Protein and Polypeptide LaboratoryVerdunCanada
  4. 4.Douglas Hospital Research CentreVerdunCanada

Personalised recommendations